List of Cadila Pharmaceuticals patents

List of Cadila Pharmaceuticals patents

List of MapR Technologies patents

List of Nearmap patents

List of Lisle Corporation patents

List of funding rounds for Wyze Labs

Intellectual property venture capital investors

Patents where

Current Assignee

Name

is

Cadila Pharmaceuticals

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 9474727 Pharmaceutical compositions of curcumin	Patent 9474727 was granted and assigned to Cadila Pharmaceuticals on October, 2016 by the United States Patent and Trademark Office.		Cadila Pharmaceuticals		United States Patent and Trademark Office	9474727	October 25, 2016
	‌ US Patent 9714275 Cancer antigen	Patent 9714275 was granted and assigned to Cadila Pharmaceuticals on July, 2017 by the United States Patent and Trademark Office.		Cadila Pharmaceuticals		United States Patent and Trademark Office	9714275	July 25, 2017
	‌ US Patent 11219674 Therapeutic cancer vaccine	Patent 11219674 was granted and assigned to Cadila Pharmaceuticals on January, 2022 by the United States Patent and Trademark Office.	Cadila Pharmaceuticals	Cadila Pharmaceuticals		United States Patent and Trademark Office	11219674	January 11, 2022
	‌ US Patent 8048434 Vaccine adjuvants	Patent 8048434 was granted and assigned to Cadila Pharmaceuticals on November, 2011 by the United States Patent and Trademark Office.		Cadila Pharmaceuticals		United States Patent and Trademark Office	8048434	November 1, 2011
	‌ US Patent 8647643 Farnesoid-X-receptor antagonist as a vaccine adjuvant	Patent 8647643 was granted and assigned to Cadila Pharmaceuticals on February, 2014 by the United States Patent and Trademark Office.		Cadila Pharmaceuticals		United States Patent and Trademark Office	8647643	February 11, 2014
	‌ US Patent 9029567 Hypoglycemic compounds	Patent 9029567 was granted and assigned to Cadila Pharmaceuticals on May, 2015 by the United States Patent and Trademark Office.		Cadila Pharmaceuticals		United States Patent and Trademark Office	9029567	May 12, 2015
	‌ US Patent 9415078 Method of treating desmocollin-3 expressing cancer with	Patent 9415078 was granted and assigned to Cadila Pharmaceuticals on August, 2016 by the United States Patent and Trademark Office.	Cadila Pharmaceuticals	Cadila Pharmaceuticals		United States Patent and Trademark Office	9415078	August 16, 2016
	‌ US Patent 10335472 Therapeutic cancer vaccine	Patent 10335472 was granted and assigned to Cadila Pharmaceuticals on July, 2019 by the United States Patent and Trademark Office.	Cadila Pharmaceuticals	Cadila Pharmaceuticals		United States Patent and Trademark Office	10335472	July 2, 2019
	‌ US Patent 9345683 Pharmaceutical composition of taxoids	Patent 9345683 was granted and assigned to Cadila Pharmaceuticals on May, 2016 by the United States Patent and Trademark Office.		Cadila Pharmaceuticals		United States Patent and Trademark Office	9345683	May 24, 2016
	‌ US Patent 9708258 Indole 3-carbinol derivatives	Patent 9708258 was granted and assigned to Cadila Pharmaceuticals on July, 2017 by the United States Patent and Trademark Office.	Cadila Pharmaceuticals	Cadila Pharmaceuticals		United States Patent and Trademark Office	9708258	July 18, 2017
	‌ US Patent 8110204 Method of treating human-immunodeficiency virus (HIV) disease infection	Patent 8110204 was granted and assigned to Cadila Pharmaceuticals on February, 2012 by the United States Patent and Trademark Office.		Cadila Pharmaceuticals		United States Patent and Trademark Office	8110204	February 7, 2012
	‌ US Patent 9795659 Pharmaceutical composition of killed cells with substantially retained immunogenicity	Patent 9795659 was granted and assigned to Cadila Pharmaceuticals on October, 2017 by the United States Patent and Trademark Office.		Cadila Pharmaceuticals		United States Patent and Trademark Office	9795659	October 24, 2017
	‌ US Patent 8277778 Vaccine adjuvants	Patent 8277778 was granted and assigned to Cadila Pharmaceuticals on October, 2012 by the United States Patent and Trademark Office.		Cadila Pharmaceuticals		United States Patent and Trademark Office	8277778	October 2, 2012
	‌ US Patent 8153102 Process for manufacturing pharmaceutical composition comprises of	Patent 8153102 was granted and assigned to Cadila Pharmaceuticals on April, 2012 by the United States Patent and Trademark Office.		Cadila Pharmaceuticals		United States Patent and Trademark Office	8153102	April 10, 2012
	‌ US Patent 7972609 Method of treating cancer	Patent 7972609 was granted and assigned to Cadila Pharmaceuticals on July, 2011 by the United States Patent and Trademark Office.		Cadila Pharmaceuticals		United States Patent and Trademark Office	7972609	July 5, 2011
	‌ US Patent 9789187 Stable pharmaceutical composition for atherosclerosis	Patent 9789187 was granted and assigned to Cadila Pharmaceuticals on October, 2017 by the United States Patent and Trademark Office.		Cadila Pharmaceuticals		United States Patent and Trademark Office	9789187	October 17, 2017
	‌ US Patent 8333978 Poly TLR antagonist	Patent 8333978 was granted and assigned to Cadila Pharmaceuticals on December, 2012 by the United States Patent and Trademark Office.		Cadila Pharmaceuticals		United States Patent and Trademark Office	8333978	December 18, 2012
	‌ US Patent 8563517 Dipeptidyl peptidase IV (DP-IV) compounds	Patent 8563517 was granted and assigned to Cadila Pharmaceuticals on October, 2013 by the United States Patent and Trademark Office.		Cadila Pharmaceuticals		United States Patent and Trademark Office	8563517	October 22, 2013

18 results

0 selected

18 results

0 selected